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Follicular cell-derived well-differentiated thyroid cancer, papillary (PTC) and follicular thy-
roid carcinomas comprise 95% of all thyroid malignancies. Familial follicular cell-derived
well-differentiated thyroid cancers contribute 5% of cases. Such familial follicular cell-
derived carcinomas or non-medullary thyroid carcinomas (NMTC) are divided into two
clinical–pathological groups. The syndromic-associated group is composed of predomi-
nately non-thyroidal tumors and includes Pendred syndrome, Warner syndrome, Carney
complex (CNC) type 1, PTEN -hamartoma tumor syndrome (PHTS; Cowden disease), and
familial adenomatous polyposis (FAP)/Gardner syndrome. Other conditions with less estab-
lished links to the development of follicular cell-derived tumors include ataxia–telangiectasia
syndrome, McCune Albright syndrome, and Peutz–Jeghers syndrome. The ﬁnal group
encompasses syndromes typiﬁed by NMTC, as well as pure familial (f) PTC with or with-
out oxyphilia, fPTC with multinodular goiter, and fPTC with papillary renal cell carcinoma.
This heterogeneous group of diseases does not have the established genotype–phenotype
correlations known as in the familial C-cell-derived tumors or medullary thyroid carcinomas
(MTC). Clinicians should have the knowledge to identify the likelihood of a patient pre-
senting with thyroid cancer having an additional underlying familial syndrome stemming
from characteristics by examining morphological ﬁndings that would alert pathologists to
recommend that patients undergo molecular genetic evaluation.This review discusses the
clinical and pathological ﬁndings of patients with familial PTC, such as FAP, CNC, Werner
syndrome, and Pendred syndrome, and the heterogeneous group of familial PTC.
Keywords: familial thyroid carcinoma, familial adenomatous polyposis, Cowden syndrome, Carney complex,
Pendred syndrome,Werner syndrome, familial papillary thyroid carcinoma
INTRODUCTION
Malignant thyroid tumors account for 1% of all malignant tumors
(American Cancer Society, 2007). The incidence of thyroid malig-
nancy has increased more than that of any other cancer (Horner
et al., 2009). Newly reported cases of thyroid cancer in the United
States grew from 18,000 in 2000 to 35,000 in 2007 (Horner et al.,
2009). This is likely due to advancements in diagnostic techniques
and early detection of small thyroid nodules (microcarcinomas),
which clinical meaning is uncertain (Zhu et al., 2009). Almost
95% of patients have well-differentiated cancer of follicular cell
origin, including papillary (80–90%), and follicular (10–15%).
Approximately 5% of patients have medullary thyroid cancer.
Advances in molecular genetics have also conﬁrmed the pres-
ence of several familial cancer syndromes with non-medullary
familial thyroid cancers, usually papillary or follicular cancers.
These include familial adenomatous polyposis (FAP), Cowden
syndrome (CS), Werner syndrome, Carney complex (CNC), and
Pendred syndrome (Dotto and Nosé, 2008; Nosé, 2008; Vriens
et al., 2009).
Familial follicular cell-derived tumors may account 5–15% of
thyroid carcinoma cases. A classiﬁcation of familial follicular cell
thyroid cancer associated with hereditary syndromes (Dotto and
Nosé, 2008; Nosé, 2008) is shown in Table 1. The inheritance, gene
involved, and risks of familial cancer syndromes for developing
thyroid cancer are also shown in Table 1.
FAMILIAL ADENOMATOUS POLYPOSIS
Familial adenomatous polyposis is inherited as an autosomal dom-
inant trait caused by a germline mutation in the adenomatous
polyposis coli (APC) gene. The APC gene is a tumor suppressor
gene on chromosome 5q21 (Spigelman et al., 1989; Luk, 1995;
Cetta et al., 2000). Patients typically have thousands of adenomas
that are primarily located in the colon and rectum. Virtually all
patients will progress to colorectal cancer if FAP is not identi-
ﬁed and treated surgically with proctocolectomy. Most patients
also develop gastric polyps of the fundus, most of which do
not progress to carcinoma. Polyps in the duodenum and peri-
ampullary region are adenomatous, with an increased risk for
progression to cancer estimated to be 200 times greater than that
of patients in the general population (Spigelman et al., 1989; Luk,
1995; Cetta et al., 2000).
Patients may have extraintestinal manifestations that include
osteomas,dental abnormalities, epidermal cysts,desmoids tumors,
congenital hypertrophy of the retinal pigment epithelium
(CHRPE), hepatoblastoma, medulloblastoma, and thyroid can-
cers.
Patients with FAP are at risk for developing papillary thyroid
carcinoma (PTC). PTC is one of the extracolonic manifestations
of FAP.Young women with FAP are at particular risk of developing
thyroid cancer, with risk approximately 160 times higher than that
of normal individuals, and PTC occurs with a frequency about
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Table 1 | Hereditary tumor syndromes associated with thyroid cancer.
Disease Histological type Gene mutation Location Incidence of
thyroid cancer
Pathological
variant of PTC
FAP and Gardner syndrome PTC APC tumor suppressor gene 5q21 2–12% Cribriform-morular
classical variant
Cowden syndrome FTC, PTC, C-cell hyperplasia PTEN tumor suppressor gene 10q23.2 >10%
Carney complex FTC, PTC PRKAR1-x 2p16 17q22–24 60 and 4%
Werner syndrome FTC, PTC, ATC WRN gene 8p11–p12 18%
PTC, papillary thyroid cancer; FAP, familial adenomatous polyposis; APC, adenomatous polyposis coli; FTC, follicular thyroid cancer; PTEN, phosphatase and tensin;
PRKAR1-x protein kinase A regulatory subunit type 1-alpha; ATC, anaplastic thyroid cancer; WRN, Werner.
10 times that expected for sporadic PTC (Harach et al., 1994;
Cameselle-Teijeiro and Chan, 1999; Soravia et al., 1999). Preva-
lence ranges from 2 to 12% of patients with FAP (Herraiz et al.,
2007).
Thyroid carcinomas associated with FAP are typically bilateral
and multifocal, with histological features different from sporadic
tumors, with characteristic histopathological cribriform pattern
with solid areas and a spindle cell component, and are most often
associated with marked ﬁbrosis (Figure 1). The characteristic
cellular and nuclear ﬁndings of sporadic PTC as grooved, over-
lapping, and clear nuclei are absent in this subtype (Harach et al.,
1994; Cameselle-Teijeiro and Chan, 1999; Soravia et al., 1999).
The cribriform-morular variant of PTC (CMv-PTC) is a very
rare subtype of PTC representing 0.1–0.2% of cases, or less than
1 in 500 cases of all papillary carcinoma cases (Harach et al.,
1994; Cameselle-Teijeiro and Chan, 1999). The overall progno-
sis for CMv-PTC is similar to that of classical variants of PTC with
less than 10% of cases demonstrating aggressive clinical behav-
ior. Among patients with FAP who have synchronous PTC, over
90% of these cases have been reported to cribriform-morular
variant. While not all CMv-PTC is associated with FAP, a signif-
icant proportion of cases are associated with FAP. Patients with
cribriform-morular variant PTC should be evaluated for FAP.
This form of PTC is typically bilateral, presents at a younger age,
and is 10 times more common in female patients with FAP. The
histology of CMv-PTC is characterized by cribriform, solid, and
morular areas lacking typical nuclear features of PTC and CMv-
PTC is associated with germline and somatic mutations in the
APC and β-catenin genes. In contrast to conventional PTC, CMv-
PTC rarely metastasizes and carries a benign prognosis. CMv-
PTC is revealed by aberrant nuclear and cytoplasmic expression
of β-catenin (β-catenin immunostaining is strong in cytoplasm
and nuclei in the morular and cribriform areas, and it is only
expressed in cell membrane of the non-tumoral follicular cells;
Figure 2).
As with other familial non-medullary thyroid carcinoma
(FNMTC) syndromes, the low incidence in FAP patients sug-
gests that PTC occurs primarily as a result of a susceptibility gene.
Somatic mutations of RET–PTC1 and RET–PTC3 have been iden-
tiﬁed. Investigators have also identiﬁed differences in the location
of APC germline mutations in FAP patients with and without
PTC (Cetta et al., 2000). They found that 13/15 (87%) patients
with FAP-associated PTC had germline mutations and that 12 of
FIGURE 1 | Cribriform-morular variant of PTC showing typical
cribriform arrangement composed of fused follicles lined by tall cells
and lumina lacking colloid (H&E).
FIGURE 2 | Immunostaining for β-catenin reveals an aberrant nuclear
and cytoplasmic staining in the cribriform-morular variant of papillary
thyroid carcinoma.The endothelial cells are negative.
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these patients had mutations in the genomic region associated
with CHRPE and in the mutation cluster region in the 5′ region
of exon 15. This led to a recommendation that thyroid screening
begin early (age 15 years) in patients or kindred with CHRPE and
for patients with exon 15 mutations in the 5′ region (Cetta et al.,
2000).
PTEN -HAMARTOMA TUMOR SYNDROME
Cowden syndrome is an autosomal dominant disorder caused by
a germline mutation in PTEN (phosphatase and tensin homolog,
deleted on chromosome 10) and characterized by the develop-
ment of multiple hamartomas and carcinomas of the thyroid,
breast, and uterus. PTEN is a tumor suppressor gene located on
10q23.3. Two-thirds of CS patients develop thyroid tumors includ-
ing multinodular goiter,multiple adenomatous nodules, follicular
adenoma, follicular carcinoma and, less frequently, PTC (Parisi
et al., 2001; Zambrano et al., 2004). The majority of thyroid lesions
occurring in PHTS are of follicular origin and are characteristi-
callymulticentric, bilateral, benign, andmalignant thyroid lesions.
Adenomatous nodules seen in PHTS are bilateral,more numerous,
and distinct from age-related nodules with only a scant atrophic
rim of normal thyroid follicles (Nosé, 2010).
Follicular carcinoma is a major criteria and an important
feature in PTEN -hamartoma tumor syndrome (PHTS). These
tumors are more frequently multicentric, and progress from a
preexisting follicular adenoma. However, PTC is rarely associated
with this entity. Multiple adenomatous nodules in a background
of lymphocytic thyroiditis and/orC-cell hyperplasia are distinctive
ﬁndings in this syndrome. Pathologists should notify clinicians of
the possibility of PHTS (Dotto and Nosé, 2008).
The diagnosis of a thyroid lesion usually precedes the diagnosis
of PHTS by many years. In some patients, a work-up for PHTS is
triggered by unusual pathologic ﬁndings in the thyroid of a young
patient, most speciﬁcally, multiple adenomatous nodules.
The current diagnostic criteria for CS include follicular carci-
noma (present in 10–15%) as a major criterion, while multinodu-
lar goiter (includingmultiple adenomatous nodules) and follicular
adenomas are minor criteria (present in 50–67%).
Adenomatous nodules are unusually numerous in these cases
reaching over 100 nodules, are not encapsulated, homogeneous,
ﬁrm, yellow-tan, lack gelatinous colloid, and do not exhibit sec-
ondary changes.Histologically, the adenomatous nodules in PHTS
are solid, cellular, and composed of small follicles lacking abun-
dant colloid, side by side with others. Some nodules may have
a thin, discontinuous rim of ﬁbrous tissue simulating a capsule
(Nosé, 2011). On immunohistochemical staining, 63% of CS cases
showed complete loss of PTEN expression and 38% showed het-
erogeneous loss of PTEN (Figure 3). All intact PTEN expression
cases were non-CS patients (Barletta et al., 2011).
The high incidence of thyroid pathology in patients with CS
warrants routine thyroid screening with ultrasonography and a
low threshold for recommending thyroidectomy.
CARNEY COMPLEX
The CNC is a dominantly inherited syndrome characterized by
spotty skin pigmentation, endocrine overactivity, and myxomas.
FIGURE 3 | Immunohistochemistry for PTEN shows loss of PTEN
expression in an adenomatous nodule in a PTEN-hamartoma tumor
syndrome (Cowden’s disease) patient. Note positivity in the endothelial
cells.
The syndrome was ﬁrst described in 1985 as “myxomas, spotty
pigmentation, and endocrine overactivity” (Carney et al., 1985).
Carney complex is deﬁned by the association of multiple
endocrine neoplasia and cardiocutaneous manifestations. Patients
previously characterized as having LAMB (lentigines, atrial myx-
oma, mucocutaneous myxoma, blue nevi) or NAME (nevi, atrial
myxoma, myxoid neuroﬁbroma, ephelide) could be considered
to have CNC. Numerous organs may be involved in CNC and
manifestations vary greatly among patients. Skin pigmentation
anomalies include lentigines and blue nevi. Myxomas can occur
at multiple sites such as the heart, skin or soft tissue, external
auditory canal, and breast. Cardiac myxomas can develop in any
cardiac chamber and may be multiple. These patients may also
present with schwannomas and testicular tumors (Stratakis et al.,
1997, 1998).
The most common endocrine gland involvements are growth
hormone (GH)-secreting pituitary adenomas (acromegaly),
thyroid tumors, and adrenocorticotropic hormone (ACTH)-
independent Cushing’s syndrome due to primary pigmented
nodular adrenocortical disease (PPNAD).
Most cases of this autosomal dominant condition are classiﬁed
as type 1 and are associatedwith amutation to the protein kinaseA
regulatory subunit type 1-alpha (PRKAR1-α) gene. Type 2 patients
have been conﬁrmed to have a mutation on chromosome 2p16,
which may be a regulator of genomic stability (Stratakis et al.,
1997; Matyakhina et al., 2003; Pan et al., 2010).
The risk of thyroid cancer is low, and the presence of thyroid
nodules is very common. The thyroid is multinodular with mul-
tiple adenomatous nodules and follicular adenomas. Both PTC
and follicular thyroid carcinomas (FTC) are present in about 15%
of patients with CNC. A recent review of CNC in 53 patients of
12 kindred found clinically signiﬁcant thyroid disease in 11% of
patients (Stratakis et al., 1997).
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WERNER SYNDROME
Werner syndrome is a rare premature aging syndrome (progeroid)
that typically begins in the third decade. The clinical presentation
includes an elderly appearance with thin skin, wrinkles, alope-
cia, and muscle atrophy in proportion to the patient’s age. The
patients with this syndrome have short stature secondary to an
absent pubertal growth period (Nehlin et al., 2000; Muftuoglu
et al., 2008). Patients also present with age-related disorders such
as diabetes, osteoporosis, cataracts, peripheral vascular disease, or
different types of malignant tumors. Malignancy and cardiac dis-
ease are the most common causes of death in these patients, who
have a median life expectancy of 54 years (Nehlin et al., 2000;
Muftuoglu et al., 2008).
It is an autosomal recessive disease that is caused by mutations
in the WRN gene on chromosome 8p11–p12. This WRN gene
encodes a protein that is both a RecQ helicase and exonuclease. It
is important in DNA repair and replication.
Patients present at a younger age and have approximately
a threefold increased risk for follicular carcinoma and six
times increased risk for developing anaplastic thyroid carcinoma
(Ishikawa et al., 1999).
The overall incidence of thyroid cancer in Japanese patients
with Werner syndrome is 18% (Ishikawa et al., 1999). The risk
of PTC is increased, speciﬁcally in Caucasian populations. This
high prevalence of thyroid cancer in Werner syndrome supports
routine thyroid screening in patients with this disorder.
FAMILIAL NON-MEDULLARY THYROID CARCINOMA
SYNDROME
Familial non-medullary thyroid carcinoma syndrome is diagnosed
when three or more family members have non-medullary thyroid
cancer in the absence of other known associated syndromes. Sta-
tistical estimates suggest that a grouping of two family members
with non-medullary thyroid carcinomas (NMTC) could represent
the concurrence of sporadic tumors, but thyroid tumors in three
or more members in kindred, or the diagnosis of PTC in men and
children, is more suggestive of a familial predisposition (Malchoff
et al., 1999; Musholt et al., 2000; Hemminki et al., 2005; Stur-
geon and Clark, 2005; Charkes, 2006). The search for a genetic
susceptibility locus for FNMTC started about a decade ago.
Familial non-medullary thyroid carcinoma is now recognized
as a distinct clinical entity and accounts for up to 10.5% of all fol-
licular cell origin thyroid carcinomas. FNMTChas been associated
with the presence of multiple benign nodules, to behave in a more
aggressive clinical behavior, and to have a worse prognosis than
sporadic non-medullary thyroid cancer. Individuals with FNMTC
have an increased risk of multifocal disease, local invasion, and
increased local or regional recurrence, lymphnodemetastases, and
intraglandular dissemination. FNMTC is an independent predic-
tor of shorter disease-free survival (Malchoff et al., 1999; Alsanea
et al., 2000; Musholt et al., 2000; Alsanea and Clark, 2001; Hem-
minki et al., 2005; Sturgeon andClark, 2005; Charkes, 2006;Mazeh
et al., 2012).
The genetic inheritance of FNMTC remains unknown, but it is
believed to be autosomal dominant with incomplete penetrance
and variable expressivity. Genetic analyses of large FNMTC kin-
dreds not only support the hypothesis of an inherited genetic
predisposition to FNMTC, but also represent the ﬁrst steps in
identiﬁcation of the putative susceptibility genes (Lesueur et al.,
1999; McKay et al., 1999; Malchoff et al., 2000; Bevan et al., 2001;
Harach, 2001; Xing, 2005). Six potential regions for harboring
an FNMTC gene have been identiﬁed: MNG1 (14q32), thyroid
carcinoma with oxyphilia (TCO; 19p13.2), fPTC/papillary renal
neoplasia (PRN; 1q21), NMTC1 (2q21), FTEN (8p23.1–p22), and
the telomere–telomerase complex. Linkage analyses have iden-
tiﬁed three different chromosomal regions that may harbor an
FNMTC susceptibility gene (Nosé, 2010).
The systematic use of an algorithmic approach will help in the
understanding of familial history and ﬁndings, and the patient’s
clinical history associated with the pathology ﬁndings to suggest
a familial disease. The clinical features and relative frequency of
different forms of familial thyroid cancer have been discussed and
presented recently (Vriens et al., 2009).
Familial tumor syndromes characterized by a predominance of
non-medullary thyroid carcinoma are listed below and summa-
rized in Table 2.
FAMILIAL PAPILLARY THYROID CARCINOMA
Papillary thyroid carcinoma in FNMTC has a well-documented
predisposition to multicentric disease, bilateral disease, local inva-
sion, extrathyroidal extension, lymphnodemetastases, recurrence,
and speciﬁc histology.
The background thyroid may show lymphocytic thyroiditis,
multinodular hyperplasia, and multiple adenomatous nodules.
Sporadic PTC has BRAF mutation in approximately 40% of cases.
However, no BRAF mutation was reported in a group of 40
patients with FNMTC as germline mutation or a susceptibility
genetic event for FNMTC (Xing, 2005).
The fPTC enriched in TCO has been mapped to chromoso-
mal region 19p13, and FNMTC without oxyphilia has also been
mapped to 19p13.31. Tumor-speciﬁc loss of heterozygosity is
found in sporadic FTC with and without oxyphilia at both 19p13
and 2q21.32 (Lesueur et al., 1999; Musholt et al., 2000).
FNMTC TYPE 1 SYNDROME
The FNMTC type 1 syndrome (chromosomal region 2q21) is char-
acterized by PTC without any distinguishing pathologic features
Table 2 | Familial tumor syndrome characterized by a predominance of
non-medullary thyroid carcinoma.
Tumor type Inheritance Chromosomal
loci
Candidate
genes
PTC associated with PRN Unknown 1q21 Unknown
Familial MNG with PTC Autosomal
dominant
14q Unknown
Familial PTC Unknown 2q21 Unknown
Familial TCO and without
oxyphilia
Autosomal
dominant
19p13.2 Unknown/
TCO/T1MM44
PRN, papillary renal cell neoplasia; PTC, papillary thyroid cancer; MNG, multin-
odular goiter; TCO, thyroid carcinoma with oxyphilia.
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and without an obvious increase in frequency of non-thyroidal
neoplasms in kindred members (McKay et al., 2001).
fPTC ASSOCIATED WITH RENAL PAPILLARY NEOPLASIA
The fPTC associated with renal papillary neoplasia presents with
the usual classical variant of PTC and with no special features.
The PRN syndrome (fPTC/PRN),mapped to chromosomal region
1q21, includes not only PTC and the expected benign thyroid
nodules, but also PRN and possibly other malignancies as well
(Malchoff et al., 2000).
FAMILIAL MULTINODULAR GOITER SYNDROME
In familial multinodular goiter syndrome, which is mapped to
14q, some patients may develop an associated PTC (Bakhsh et al.,
2006).
CONCLUSION
Mutations in patients with FNMTC syndromes have not been well
deﬁned as in medullary thyroid carcinoma (MTC). Most patients
with these familial syndromes may have susceptibility genes that
increase the risk of thyroid cancer. Thyroid cancer inmany of these
patients has been characterized as more aggressive than sporadic
thyroid cancer, with a predisposition for lymph node metastasis,
extrathyroidal invasion, and a younger age of onset. Most patients
with a familial syndrome and FNMTC will have PTC, suggest-
ing that a speciﬁc gene for PTC may also be present. In many
cases, patients have a known familial syndrome that has a deﬁned
risk for thyroid cancer. These patients can be followed closely and
the thyroid can be identiﬁed at an earlier stage (Nosé, 2010). In
a few cases, thyroid cancer may be the initial presentation of an
underlying familial syndrome.
The distinct thyroid pathology in some of these syndromes
should alert the pathologist of a possible familial cancer syn-
drome. Knowledge of FNMTC and its histopathology can allow
the pathologist to diagnose familial tumor syndrome. Awareness
and screening of FNMTC will permit earlier detection, proper
treatment, and improved outcomes for patients and their families.
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